Improvement in Mucosal Discoid Lupus Erythematosus with Anifrolumab
| Autor: | Katharina Shaw, Dustin Taylor, Stephanie Sanchez-Melendez, Julia Barker, Sarah Lonowski, Neda Shahriari, Hannah J Porter, Keith Morley, Avery LaChance, Ruth Ann Vleugels |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Clinical and Experimental Dermatology. |
| ISSN: | 1365-2230 0307-6938 |
| DOI: | 10.1093/ced/llad190 |
| Popis: | Anifrolumab is a fully humanized monoclonal antibody targeting type I interferon receptor recently approved for the treatment of moderate-to-severe systemic lupus erythematous (SLE). In addition to ameliorating systemic lupus activity, anifrolumab has emerged as a promising therapeutic option for patients with refractory cutaneous discoid lupus erythematosus (DLE), but its effect on mucosal DLE has yet to be investigated. In a prospective study of 7 patients with severe mucosal DLE treated with anifrolumab, we observed substantial improvement in mucosal disease activity within 1 month of anifrolumab initiation, suggesting that the impressive benefit of anifrolumab previously reported in cutaneous DLE extends to mucosal involvement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|